35 Results for: created: (01/2018 to 01/2018)

People

  1. Hellmann
    Hellmann
  2. Kris
    Kris
  3. Rudin
    Rudin
  4. Drilon
    Drilon
  5. Riely
    Riely
  6. Rimner
    Rimner
  7. Yu
    Yu
  8. Rusch
    Rusch
  9. Chaft
    Chaft
  10. Li
    Li

Groups

  1. Department of Medicine (35)
  2. Solid Tumor Oncology Division (35)
  3. Thoracic Oncology (35)
  4. Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center (9)
  5. GSK Faculty (9)
  6. Biostatistics Service (6)
  7. Epidemiology and Biostatistics (6)
  8. Sloan Kettering Institute Postdocs (5)
  9. Surgery (5)
  10. Center for Molecular Imaging and Biotechnology (CMIB) (4)
  1. "Thoracic Oncology"
Formats
  1. Meeting Abstract (21)
  2. Journal Article (12)
  3. Book Section (2)
Groups
  1. Department of Medicine (35)
  2. Solid Tumor Oncology Division (35)
  3. Thoracic Oncology (35)
  4. Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center (9)
  5. GSK Faculty (9)
  6. Biostatistics Service (6)

More Groups

People
  1. Charles Rudin (7)
  2. Mark Kris (7)
  3. Matthew Hellmann (7)
  4. Alexander Drilon (6)
  5. Gregory Riely (6)
  6. Andreas Rimner (5)

More People

Years
  1. 2018 (1)
  2. 2017 (32)
  3. 2016 (1)
  4. 2011 (1)
Publications
  1. Journal of Thoracic Oncology (18)
  2. Clinical Cancer Research (2)
  3. Neuro-Oncology (2)
  4. Advances in Radiation Oncology (1)
  5. Annals of Translational Medicine (1)
  6. Asbestos and Mesothelioma (1)

More Publications

Publishers
  1. Elsevier Inc. (19)
  2. American Association for Cancer Research (2)
  3. Nature Publishing Group (2)
  4. Oxford University Press (2)
  5. AME Publishing Company (1)
  6. American Association of Physicists in Medicine (1)

More Publishers

Results (35)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Twice weekly pulse and daily continuous-dose erlotinib as initial treatment for patients with epidermal growth factor receptor–mutant lung cancers and brain metastases
    Journal Article

    Arbour, K. C.; Kris, M. G.; Riely, G. J.; Ni, A.; Beal, K.; Daras, M.; Hayes, S. A.; Young, R. J.; Rodriguez, C. R.; Ahn, L.; more...
    Cancer (2018)

    Fulltext@MSK | Save
  • The development of brain metastasis in the patients with metastatic non-small cell lung cancer (NSCLC) and melanoma treated with immune checkpoint inhibitors: A retrospective analysis
    Meeting Abstract

    Chaul-Barbosa, C.; Niotis, K.; Hellmann, M.; Callahan, M.; Daras, M.
    Neuro-Oncology (2017)

    Fulltext@MSK | Save
  • Prognostic factors and outcomes of patients with central nervous system (CNS) metastatic ALK-rearranged non-small cell lung cancer (NSCLC)
    Meeting Abstract

    Kachur, E.; Reiss, S.; Land, J.; Buie, L.; Reiner, A.; Panageas, K.; Riely, G.; Pentsova, E.
    Neuro-Oncology (2017)

    Fulltext@MSK | Save
  • Phase II trial of the c-Met inhibitor tepotinib in advanced lung adenocarcinoma with MET exon 14 skipping mutations after failure of prior therapy
    Meeting Abstract

    Paik, P.; Stammberger, U.; Bruns, R.; Overton, L.
    Journal of Thoracic Oncology (2017)

    Fulltext@MSK | Save
  • Clinical activity of osimertinib in EGFR mutation positive non-small cell lung cancer (NSCLC) patients (pts) previously treated with rociletinib
    Meeting Abstract

    Gadgeel, S.; Chen, W.; Piotrowska, Z.; Goldman, J. W.; Wakelee, H.; Camidge, D. R.; Varga, A.; Yu, H.; Papadimitrakopoulou, V.; Nea, J.; more...
    Journal of Thoracic Oncology (2017)

    Fulltext@MSK | Save
  • Safety, clinical activity and biomarker results from a phase lb study of erlotinib plus atezolizumab in advanced NSCLC
    Meeting Abstract

    Rudin, C.; Cervantes, A.; Dowlati, A.; Besse, B.; Ma, B.; Costa, D.; Schmid, P.; Heist, R.; Villaflor, V.; Sarkar, I.; more...
    Journal of Thoracic Oncology (2017)

    Fulltext@MSK | Save
  • Phase 1 study of ramucirumab or necitumumab in combination with osimertinib (AZD9291) in advanced T790M-positive EGFR-mutant NSCLC
    Meeting Abstract

    Planchard, D.; Kris, M.; Besse, B.; Hozak, R.; He, S.; Gan, F.; Wolff, K.; Chao, B.; Yu, H.
    Journal of Thoracic Oncology (2017)

    Fulltext@MSK | Save
  • A phase II study of atezolizumab as neoadjuvant and adjuvant therapy in patients (pts) with resectable non small cell lung cancer (NSCLC)
    Meeting Abstract

    Owen, D.; Bunn, P. Jr; Johnson, B.; Kwiatkowski, D.; Kris, M.; Wistuba, I.; Gandhi, M.; Phan, S.; Shames, D.; Schulze, K.; more...
    Journal of Thoracic Oncology (2017)

    Fulltext@MSK | Save
  • SBRT and sequential chemotherapy for stage IIA to IIIA non-small cell lung cancer - A phase I dose escalation study
    Meeting Abstract

    Von Reibnitz, D.; Chaft, J.; Wu, A.; Gelblum, D.; Yorke, E.; Gelb, E.; Mitchell, S.; Ng, K.; Rimner, A.
    Journal of Thoracic Oncology (2017)

    Fulltext@MSK | Save
  • Antitumor activity and safety of crizotinib in patients with MET exon 14-altered advanced non-small cell lung cancer
    Meeting Abstract

    Drilon, A.; Ou, S. H.; Clark, J.; Camidge, D. R.; Socinski, M.; Weiss, J.; Solomon, B.; Riely, G.; Heist, R.; Shapiro, G.; more...
    Journal of Thoracic Oncology (2017)

    Fulltext@MSK | Save